Business Wire

Metanoia Announces the Closing of a $19.3M New Round of Funding and Its Entry Into the 5G Market

Share

Metanoia Communications Inc. (Metanoia), a leading manufacturer of standalone high-speed xDSL and Gfast PHY chipsets for the wireline broadband market, is excited to announce that it has successfully completed its most significant fundraising in the history of the company from a stellar consortium of domestic investors led by Taiwania Capital Investment and National Development Fund. Elan Microelectronics, the original primary investor in Metanoia, is also participating in this new round of investment.

“Introduction of new and innovative products is a key area of focus in Metanoia’s strategy and this new round of investment will enable Metanoia to develop and release 5G chips for Remote Radio Units (RRU), Small Cells and CPEs in near future,” said Chien-Te Wu, Metanoia President & CEO. “The company will further capitalize on and broaden its established position as a recognized leader in the Broadband Wireline markets, where our employees are striving to enhance the overall customer experience, while deepening relationships with existing and new customers.”

Taiwania Capital CEO David Weng added: “Taiwania Capital Investment is very excited about investing in Metanoia as it embarks on a new journey with its strategic decision to diversify into the 5G market with the introduction of exciting new products with significant potential and market prospects.”

The funding will also be used to support the launch of Metanoia’s new Gfast / VDSL2 family of chipsets and is also expected to drive further international adoption and expansion.

5G solutions are rapidly moving beyond just providing indoor coverage within buildings or arenas, and are becoming strategic enablers of outdoor network densification for Services Providers and will be the key components in strengthening the Service Providers’ 5G deployments. Building chips that can serve both RRU and Small Cell markets as well as the CPE is an important element of Metanoia’s product strategy to meet these requirements.

“By developing our innovative and highly programmable architecture for our Broadband Wireline products, and by leveraging our partners’ knowledge in 5G technology, Metanoia quickly realized that it could adapt and use existing technology and apply it to certain 5G market segments,” added Didier Boivin, Metanoia executive vice president. “While the medium is different than what Metanoia has previously served, (wireless vs. wireline), there are significant overlaps at the physical layer (PHY) enabling Metanoia to leverage its existing technology and quickly come up with new 5G products and enable our current and future customers to meet the market requirements.”

“Taiwan is embarking on a strategy and plan for deploying 5G in both public and private enterprise networks in 2020. Key goals in Taiwan’s 5G program include providing end-end solutions in enterprise network for vertical applications and obtaining significant market shares for 5G related products,” said Dr. Li Fung Chang, CTO, 5G Technology Program Office, Ministry of Economic Affairs(MoEA). “To achieve these goals, it is counting on its domestic enterprises to contribute to the success of the program. Several companies are already enlisted from server companies to chipset companies like Metanoia. Upcoming new 5G products from Metanoia will bring the flexibility needed to implement features which could be helpful in quickly adapting to the changing market requirements and thereby creating lasting differentiators to the market.”

Metanoia will next participate at COMPUTEX 40th in Taipei, Taiwan from June 2nd to June 6th 2020.

Please come to visit us.

About Metanoia Communications, Inc.

Metanoia Communications, a subsidiary of Elan Microelectronics, was established in Hsinchu Science Park, Taiwan. Since its inception, Metanoia has been contributing to the development of several generations of semiconductor and software solutions for the wireline Broadband and the in-home networking markets, delivering to broadband manufacturers very high-speed PHY devices with reliable and superior performances.

For more information about Metanoia, please visit our website at www.metanoia-comm.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Metanoia Communications Inc.
Ting Liao
Email: sales@metanoia-comm.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Daiichi Sankyo Shines a Light on Inequalities and Unmet Needs in Care as Part of Its Commitment to People With Cardiovascular Disease31.8.2024 17:00:00 CEST | Press release

Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care, by shining a light on inequalities in treatment and outcomes experienced by various patient groups. The announcement follows the presentation of data from sub-analyses of the SANTORINI observational study and ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular Atrial Fibrillation) study programme, at the European Society of Cardiology (ESC) Congress 2024. Gender inequalities in CV disease treatment and LDL-C goal attainment Raised low-density lipoprotein cholesterol (LDL-C) is a key modifiable contributor to risk of cardiovascular major events. It has been shown that for every 1 mmol/L reduction in LDL-C, there is a 22% reduction in major cardiovascular events after 1 year.7,8 Female patients in Europe who are at high or very high CV risk were undertreated and less achieved guideline-recomm

Suzano completes purchase of 15% stake in Lenzing AG31.8.2024 00:40:00 CEST | Press release

Suzano, the world's largest pulp producer, today announces the completion of its acquisition of a 15% stake in Lenzing AG, the Vienna-listed leading global supplier of sustainable premium cellulosic fibres for the textile and non-wovens industry, from B&C Group. As announced in June this year, the transaction value is EUR 230 million (or EUR 39.70 per share). The agreement was subject to regulatory approval, which was granted without restrictions. The long-term partnership between Suzano and B&C Group establishes that Suzano has the right to hold two seats on Lenzing’s Board and the option to acquire an additional 15% stake from B&C Group until the end of 2028. Following the sale of the 15% stake, B&C Group now holds 37.25% of Lenzing’s share capital. Lenzing is a leading global supplier of premium wood-based cellulosic fibers (lyocell, modal, and viscose) for the production of clothing, home textiles, hygiene products, and non-woven materials. Beto Abreu, CEO of Suzano, said: “Lenzing

Ant International Collaborates with Brazilian Partners to Drive Financial Inclusion with Innovative Credit Tech Solutions30.8.2024 20:46:00 CEST | Press release

Ant International, a digital payment and financial technology leader, today announced its strategic initiative to provide AI-driven credit technology solutions designed to empower local partners and advance financial inclusions in Brazil. As a major milestone, Ant International has formed a strategic partnership with Dock, a leader in payments and banking technology in Latin America. This collaboration aims to enhance the credit management capability and infrastructure efficiency for Dock’s clients, which include financial institutions, retailers, fintech start-ups, etc. The shared vision is to make credit services more inclusive for market segments that are currently insufficiently served, such as micro, small and medium-sized enterprises (MSMEs). In the initial phase of the collaboration, Ant International’s AI-driven credit tech solutions, including an automated and intelligent risk management engine, will be explored for integration into Dock One platform. This initiative aims to s

Wipro Appoints Srikumar Rao as Global Head of Its Engineering Edge Business Line30.8.2024 16:20:00 CEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, today announced the appointment of Srikumar Rao as Global Head of its Engineering Edge Business Line, effective from October 5, 2024. Srikumar succeeds Harmeet Chauhan, who is stepping down to pursue opportunities outside the organization. Srikumar will report to Srini Pallia. Srikumar has been with Wipro for 26 years and has grown with the organization, serving in various leadership roles. He was most recently the Chief Operating Officer (COO) of Wipro Engineering Edge (WEE) and Global Practice Head of Embedded Systems. His work has spanned several markets, selling and delivering specialized Engineering, Research, and Development (ER&D) services to Software & Internet, Semiconductor, Automotive, Manufacturing, and Communications clients. In his new role, Srikumar will continue to scale and strengthen Wipro’s engineering prowess. He will also be responsible for defining the vision

Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress30.8.2024 12:00:00 CEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). The data were presented today in a Hot Line session at the European Society of Cardiology (ESC) Congress 2024, taking place August 30-September 2 in London, United Kingdom. Results from the HELIOS-B study were also simultaneously published in TheNew England Journal of Medicine. As previously reported, the HELIOS-B study met all 10 of its primary and secondary endpoints, across both the overall and monotherapy populations, with statistical significance. Enrolled patients were predominantly New York Heart Association (NYHA) Class I or II with wild-type disease and had been diagnosed by non-invasive methods, with substantial concurrent treatment with available standard of care treatments such as tafamidis and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye